Advancing diagnostics for Chagas disease: key product characteristics and harmonized evaluation strategies - an expert meeting report - Takeaways - MDSpire

Advancing diagnostics for Chagas disease: key product characteristics and harmonized evaluation strategies - an expert meeting report

  • By

  • Laura C. Bohorquez

  • Alejandro G. Schijman

  • Freddy Perez

  • Hector Coto

  • Andrea Marchiol

  • Maria-Jesus Pinazo

  • June 17, 2026

  • 0 min

Share

  • 1

    Approximately seven million people are infected with Trypanosoma cruzi, causing Chagas disease, with over 10,000 related deaths annually.

  • 2

    Barriers to healthcare access include a costly diagnosis process and limited availability of diagnostics in primary health centers.

  • 3

    A scientific meeting with 44 experts focused on RDT validation, molecular test standards, and cost-effectiveness frameworks for Chagas disease.

  • 4

    The meeting resulted in a harmonized protocol for evaluating RDTs, published by PAHO as the first standardized guideline for CD RDT evaluation.

  • 5

    Experts reached consensus on key product characteristics and quality standards for molecular tests to improve early diagnosis of T. cruzi infection.

Original Source(s)

Advancing diagnostics for Chagas disease: key product characteristics and harmonized evaluation strategies - an expert meeting report

  • by Laura C. Bohorquez, Alejandro G. Schijman, Freddy Perez, Hector Coto, Andrea Marchiol, Maria-Jesus Pinazo

  • June 17, 2026

Related Content

Symptom burden, lung function, exercise tolerance and inflammation in patients post COVID-19: results from the prospective COVID-19 Chronic Morbidity (CCHROMO) study

Cardiovascular sequelae of Long COVID: immune dysregulation inflammation as central drivers

ABO gene polymorphisms: a molecular bridge linking disease susceptibility to therapeutic outcomes